Suppression of MAPKs/NF-κB Activation Induces Intestinal Anti-Inflammatory Action of Ginsenoside Rf in HT-29 and RAW264.7 Cells

Immunological Investigations

Volumn 45, Issue 5, 2016, Pages 439-449

  Ahn, Sungeun ^a   Siddiqi, Muhammad Hanif ^a   Aceituno, Veronica Castro ^a   Simu, Shakina Yesmin ^a   Yang, Deok Chun ^a  

^a Kyung Hee University   (South Korea)

Author keywords

Ginseng; ginsenoside Rf; inflammation; inflammatory bowel disease; NF B

Indexed keywords

GINSENOSIDE RF; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; GINSENOSIDE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION; HT 29 CELL LINE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; INFLAMMATORY BOWEL DISEASE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAW 264.7 CELL LINE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; ANIMAL; DRUG EFFECTS; HT-29 CELL LINE; INFLAMMATORY BOWEL DISEASES; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DOWN-REGULATION; GINSENOSIDES; HT29 CELLS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-1BETA; INTERLEUKIN-6; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NITRIC OXIDE; RAW 264.7 CELLS; REACTIVE OXYGEN SPECIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84969756258     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2016.1168830     Document Type: Article

References (35)

1. S.E.Ahn, M.H.Siddiqi, V.C.Aceituno, et al. (2015). Ginsenoside Rg5: Rk1 attenuates TNF-α/IFN-γ-induced production of thymus-and activation-regulated chemokine (TARC/CCL17) and LPS-induced NO production via downregulation of NF-κB/p38 MAPK/STAT1 signaling in human keratinocytes and macrophages. In Vitro Cellular & Developmental Biology-Animal, 1–9.
2. S.E.Ahn, M.H.Siddiqi, H.Y.Noh, et al. (2015). Anti-inflammatory activity of ginsenosides in LPS-stimulated RAW 264.7 cells. Science Bulletin, 60, 773–84.
3. I.Atreya, R.Atreya, M.F.Neurath (2008). NF-kappaB in inflammatory bowel disease. J Intern Med, 263, 591–6.
4. E.A.Bae, M.J.Han, Y.W.Shin, et al. (2006). Inhibitory effects of Korean red ginseng and its genuine constituents ginsenosides Rg3, Rf, and Rh2 in mouse passive cutaneous anaphylaxis reaction and contact dermatitis models. Biol Pharm Bull, 29, 1862–7.
5. K.Choi, M.Kim, J.Ryu, et al. (2002). Ginsenosides compound K and Rh 2 inhibit tumor necrosis factor-α-induced activation of the NF-κB and JNK pathways in human astroglial cells. Neurosci Lett, 421, 37–41.
6. S.Choi, S.Y.Jung, Y.S.Ko, et al. (2002). Functional expression of a novel ginsenoside Rf binding protein from rat brain mRNA in Xenopus laevis oocytes. Mol Pharmacol, 61, 928–35.
7. M.Farrokhi, M.Etemadifar, J.Alavi, et al. (2015). TNF-alpha production by peripheral blood monocytes in multiple sclerosis patients and healthy controls. Immunolo Invest, 44, 590–601.
8. I.J.Fuss (2003). Cytokine network in inflammatory bowel disease. Curr Drug Targets-Inflammation Allergy, 2, 101–112.
9. C.N.Gillis (1997). Panax ginseng pharmacology: A nitric oxide link?. Biochem Pharmacol, 54, 1–8.
10. D.Hollander (1994). Gastrointestinal complications of nonsteroidal anti-inflammatory drugs: Prophylactic and therapeutic strategies. Am J Med, 96, 274–81.
11. J.B.Jeong, Y.K.Shin, S.H.Lee (2013). Anti-inflammatory activity of patchouli alcohol in RAW264.7 and HT-29 cells. Food Chem Toxicol, 55, 229–33.
12. J.H.Kim, S.C.Gupta, B.Park, et al. (2012). Turmeric (Curcuma longa) inhibits inflammatory nuclear factor (NF)-kappaB and NF-kappaB-regulated gene products and induces death receptors leading to suppressed proliferation, induced chemosensitization, and suppressed osteoclastogenesis. Mol Nutr Food Res, 56, 454–65.
13. K.J.Kim, J.S.Lee, M.K.Kwak, et al. (2009). Anti-inflammatory action of mollugin and its synthetic derivatives in HT-29 human colonic epithelial cells is mediated through inhibition of NF-kappaB activation. Eur J Pharmacol, 622, 52–7.
14. M.E.Kim, Y.C.Jung, I.Jung, et al. (2015). Anti-inflammatory effects of ethanolic extract from Sargassum horneri (Turner) C. Agardh on lipopolysaccharide-stimulated macrophage activation via NF-κB pathway regulation. Immunol Invest, 44, 137–146.
15. H.Lee, F.J.Gonzalez, M.Yoon (2006). Ginsenoside Rf, a component of ginseng, regulates lipoprotein metabolism through peroxisome proliferator-activated receptor alpha. Biochem Biophys Res Commun, 339, 196–203.
16. Y.J.Lee, Y.M.Son, M.J.Gu, et al. (2015). Ginsenoside fractions regulate the action of monocytes and their differentiation into dendritic cells. J Ginseng Res, 39, 29–37.
17. Y.Li, Q.Wang, X.Yao, Y.Li 2010. Induction of CYP3A4 and MDR1 gene expression by baicalin, baicalein, chlorogenic acid, and ginsenoside Rf through constitutive androstane receptor- and pregnane X receptor-mediated pathways. Eur J Pharmacol, 640, 46–54.
18. J.Liu, Y.Y.Liu, J.Liu, et al. (2015). Association between CARD8 rs2043211 Polymorphism and inflammatory bowel disease: A meta-analysis. Immunological investigations, 44, 253–264.
19. L.D.Mastrandrea (2015). An overview of organ-specific autoimmune diseases including immunotherapy. Immunol Invest, 44, 803–816.
20. M.F.Neurath, I.Fuss, G.Schurmann, et al. (1998). Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease. Ann N Y Acad Sci, 859, 149–59.
21. C.Nunes, E.Ferreira, V.Freitas, et al. (2013). Intestinal anti-inflammatory activity of red wine extract: Unveiling the mechanisms in colonic epithelial cells. Food Funct, 4, 373–83.
22. S.M.Plummer, K.A.Holloway, M.M.Manson, et al. (1999). Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene, 18, 6013–20.
23. D.K.Podolsky (1991). Inflammatory bowel disease. N Engl J Med, 325, 928–37.
24. G.Rogler, K.Brand, D.Vogl, et al. (1998). Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115, 357–69.
25. H.Schmitz, M.Fromm, C.J.Bentzel, et al. (1999). Tumor necrosis factor-alpha (TNFalpha) regulates the epithelial barrier in the human intestinal cell line HT-29/B6. J Cell Sci, 112, 137–46.
26. M.H.Siddiqi, M.Z.Siddiqi, S.Ahn, et al. (2013). Ginseng saponins and the treatment of osteoporosis: Mini literature review. J Ginseng Res, 37, 261–8.
27. M.H.Siddiqi, M.Z.Siddiqi, S.Kang, et al. (2015). Inhibition of osteoclast differentiation by ginsenoside Rg3 in RAW264.7 cells via RANKL, JNK and p38 MAPK pathways through a modulation of cathepsin K: An in silico and in vitro study. Phytother Res, 29, 1286–94.
28. C.Vanderpool, F.Yan, D.B.Polk (2008). Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel diseases. Inflamm Bowel Dis, 14, 1585–96.
29. L.Vecchi Brumatti, A.Marcuzzi, P.M.Tricarico, et al. (2014). Curcumin and inflammatory bowel disease: Potential and limits of innovative treatments. Molecules, 19, 21127–53.
30. C.K.Wong, C.B.Wang, W.K.Ip, et al. (2005). Role of p38 MAPK and NF-kB for chemokine release in coculture of human eosinophils and bronchial epithelial cells. Clin Exp Immunol, 139, 90–100.
31. C.F.Wu, X.L.Bi, J.Y.Yang, et al. (2007). Differential effects of ginsenosides on NO and TNF-alpha production by LPS-activated N9 microglia. Int Immunopharmacol, 7, 313–20.
32. R.J.Xavier, D.K.Podolsky (2007). Unravelling the pathogenesis of inflammatory bowel disease. Nature, 448, 427–34.
33. X.Xu, P.Yin, C.Wan, et al. (2014). Punicalagin inhibits inflammation in LPS-induced RAW264.7 macrophages via the suppression of TLR4-mediated MAPKs and NF-kappaB activation. Inflammation, 37, 956–65.
34. R.Zhang, S.Gilbert, X.Yao, et al. (2015). Natural compound methyl protodioscin protects against intestinal inflammation through modulation of intestinal immune responses. Pharmacol Res Perspect, 3(2), e00118. doi: 10.1002/prp2.118
35. W.Zhu, J.Yu, Y.Nie, et al. (2014). Disequilibrium of M1 and M2 macrophages correlates with the development of experimental inflammatory bowel diseases. Immunological Invest, 43, 638–652.